Prelude Capital Management, LLC Regulus Therapeutics Inc. Transaction History

Prelude Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.79 - $2.8 $211,882 - $331,436	-118,370 Reduced 89.36%	14,100 $25,000
Q1 2024 May 15, 2024	BUY	$1.13 - $2.88 $104,197 - $265,564	92,210 Added 229.04%	132,470 $381,000
Q3 2023 Nov 14, 2023	SELL	$1.27 - $1.76 $508 - $704	-400 Reduced 0.98%	40,260 $55,000
Q2 2023 Aug 14, 2023	BUY	$0.87 - $1.75 $35,374 - $71,155	40,660 New	40,660 $59,000

56.5M

79.3K

20.3K

Ticker RGLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,634,400
Market Cap $24M
Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.